Diagnosing Immune Thrombocytopenia: An Update

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by increased platelet destruction and impaired platelet production, resulting in isolated thrombocytopenia. Despite advances in understanding disease pathophysiology, diagnosis remains challenging because no single clinical or laboratory test definitively establishes the diagnosis. Current international guidelines therefore continue to define ITP primarily as a diagnosis of exclusion based on clinical assessment, complete blood count, and peripheral blood smear evaluation.

Recent developments in platelet immunology and laboratory diagnostics have expanded the range of adjunctive diagnostic tools. Glycoprotein-specific platelet autoantibody assays, including monoclonal antibody immobilization of platelet antigens (MAIPA)-based methods, provide high specificity for immune-mediated platelet destruction but remain limited by moderate sensitivity and restricted standardization. Biomarkers reflecting thrombopoiesis, particularly immature platelet fraction, thrombopoietin levels, support differentiation between hyperdestructive and hypoproductive thrombocytopenia, especially when integrated into multivariable diagnostic algorithms.

Current diagnostic strategies differ across guidelines. Whereas ASH, ISTH-associated initiatives and Onkopedia recommendations emphasize restrained and clinically guided testing, the recent Japanese guideline incorporates thrombopoietin levels and immature platelet fraction into a more laboratory-oriented diagnostic framework. Overall, laboratory investigations should still be regarded as supportive rather than definitive. Future diagnostic strategies are expected to integrate clinical assessment with immunologic, thrombopoietic, and cellular biomarkers, enabling a more pathophysiology-based classification of thrombocytopenic disorders and improving diagnostic precision and individualized patient management.